Is it three steps forward one step back for blood tests? At the 18th Clinical Trials on Alzheimer’s Disease, held December 1–4 in San Diego, new data on the FDA-approved Fujirebio Lumipulse plasma ...

Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

When cells are starved or distressed, RNA and RNA-binding proteins can coalesce into membraneless liquid droplets called stress granules. These shut down translation, helping cells conserve energy.

As the trained killers of the immune system, cytotoxic T cells silently save our lives every day—vanquishing viruses before they can run amok, and putting nascent cancer cells out of business before ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

At birth, people who carry a string of more than 40 CAG repeats within the first exon of the huntingtin gene are all but destined to develop Huntington’s disease. Yet, recent studies are converging on ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...